Collaborating across the system and redesigning pharmacy services to optimise medicines value and improve outcomes 

1 October 2024 | Leonardo Royal Hotel, London City

08.00  Registration & refreshments  

08.50  Chair’s opening remarks  - Alastair McLellan, Editor, HSJ  

09.00  KEYNOTE: The National Picture for Medicines and Pharmacy 

  • With significant changes to the medicine and pharmacy landscape we hear from senior national leadership on key strategic priorities and the landscape, such as: 
  • Future of pharmacy services and the role of community pharmacy teams and independent prescribing in an integrated care environment of?  
  • The importance of patient-centred care and tailored medication management strategies to optimise health outcomes. 
  • How can effective collaboration between trusts, community pharmacy and ICS level regional strategy can effectively drive medicines optimisation 
  • The anticipated challenges such as rising healthcare costs and the need for innovation and collaboration to address them effectively. 
  • The strategic priorities for pharmacy practice, including expanding pharmacist roles in primary care and leveraging technology for enhanced patient outcomes. 
  • How are we developing digital transformation for pharmacy services? 

09.45  PANEL: How do pharmacies play a crucial part in reducing variation and health inequalities? 

  • What is our main focus for improving prescribing? 
  • How can we improve efficiency and personalisation of medicines? 
  • How are ICBs monitoring Health Inequalities and how addressing them? 
  • How do we reduce unwarranted variation, fairer equity to access of medicines and improve patients experience? 
  • How do we collaborate and foster engagement from relevant stakeholders  
  • What would it take to have a national formulary to aid the reduction of health inequalities? 

10.30 Morning refreshments & networking  

11:00 PANEL: Maximising value and outcomes through formulary reviews 

  • Ensuring a holistic view of patient and population needs when creating evidence bases for first- and second-line prescribing decision making 
  • Finding ways to balance costs, outcome measures and patient experience to ensure the greatest patient benefit is gained each time 
  • Discussing why and how industry could facilitate better data sharing and evidence bases to inform decision making 
  • Continuously assessing the impact of formulary changes on prescribing patterns to maximise value 

11:40 PANEL: Optimising outcomes through service digitization and interoperability 

  • What is the future of e-prescribing, including system-level implementation and legislative considerations? 
  • The importance of shared electronic health records for coordinated care delivery and patient safety. 
  • How is the role of technology in enhancing decision-making processes and prioritising healthcare resources? 
  • Address the need for universal access to digital healthcare systems, strategies for breaking down silos, and leveraging AI for improved patient care and outcomes. 

12:20 Innovation Showcase 

  • AI and the impact on medicines 
  • Partner innovation Showcase 
  • Partner Innovation Showcase 

12.50 Networking lunch  

13:40 Interactive Workshops: 45 min interactive workshop sessions, with three running concurrently  

  1. Empowering pharmacy teams: Future-proofing the pharmacy workforce 
  2. Deprescribing and polypharmacy: How should progress be measured? 
  3. How do we improve patient safety with medicines? 
  4. Genomics Testing  
  5. Challenges of manufacturing medicines on site / Homecare Infusion 
  6. Optimising oncology pharmacy and prescribing and upskilling the pharmacy workforce 

15:10  Afternoon refreshments & networking

15:40 PANEL: Pharmacy First: 6 Months in: How is it working so far? 

  • The framework for future commissioning of NHS Community Pharmacy 
  • How is Pharmacy First working so far in the community with a significant increased footfall into community pharmacy?​ 
  • Are we seeing the benefits in relieving pressures on GPs and primary care?  
  • How are we managing work force and training for independent prescribing  
  • Are there any teething problems in its implementation? 
  • How is this working with the ICS? 

16:20  PANEL: How are we managing devolved responsibility for specialised commissioning? 

  • Case studies how services have been redesigned following delegation?   
  • How working with neighbouring ICS? 
  • How to manage the rising costs of medications within the context of specialised commissioning 
  • Strategies for prioritizing and allocating resources effectively 
  • How are we ensuring equitable access to specialised medications across different regions and patient populations can be challenging due to variations in funding, clinical criteria, and availability of treatments? 
  • Considerations for balancing the need for innovative treatments with budget constraints 

17:20  Chair’s closing remarks